Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
More News related to SCMP
- Sucampo Pharma (SCMP) Presents Additional Clinical Data for Lubiprostone
- Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
- Sucampo Pharma (SCMP) Subsidiary Granted Marketing Authorization for Amitiza in Switzerland
- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation
- Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today reported its consolidated financial results for the quarter and nine months ended September 30, 2009.
Financial Highlights of the Quarter:
-- Product royalty revenue from sales of Amitiza(R) (lubiprostone) in the
U.S. for the third quarter of 2009 was $9.4 million compared to $7.7
million during the prior year period. Product royalty revenues had been
negatively impacted in the third quarter of 2008, as $1.9 million of
revenue was recognized in the second quarter of 2008 from the initial
stocking of Amitiza (8 mcg) for irritable bowel syndrome with
constipation (IBS-C).
-- Net sales of Amitiza, as reported by our collaboration partner Takeda
Pharmaceutical Company (Takeda), for the third quarter of 2009 grew to
$52.0 million, or by 2.4%, compared to $50.8 million the prior year
period.
-- Sucampo reported a net loss of $0.1 million, or $0.00 per diluted share,
in the third quarter of 2009 compared to net loss of $2.4 million, or
$0.06 per diluted share, in the prior year period. This favorable change
is primarily attributable to increased research and development and
product royalty revenues, decreased research and development expenses
and a change in Sucampo's taxable position.
-- The income (loss) before income taxes for each of Sucampo's reportable
segments for the third quarter of 2009 was: a pre-tax income of $3.6
million from Sucampo Pharma Americas; a pre-tax loss of $1.5 million
from Sucampo Pharma Europe; and a pre-tax loss of $0.7 million from
Sucampo Pharma Asia. These results compare with losses before income
taxes for the third quarter of 2008 of $2.8 million, $0.5 million and
$0.9 million, respectively.
-- Sucampo's consolidated cash, cash equivalents and investments increased
to $123.6 million as of September 30, 2009, from $121.5 million at
December 31, 2008. The increase is mainly attributable to payments
received under the Abbott Japan agreement, partially offset by the
upfront payment of $3.0 million to R-Tech Ueno Ltd. for the U.S. and
Canadian rights to Rescula. Sucampo had no debt as of September 30,
2009.
Operational Update:
-- In October 2009, Sucampo Pharmaceuticals, Inc. announced that William L.
Ashton, Dean of the Mayes College of Healthcare Business and Policy, at
the University of the Sciences in Philadelphia, Pennsylvania, had been
appointed to the Board of Directors. Prior to joining the university in
2005, Mr. Ashton held a number of senior executive positions at Amgen
Inc., including Business Unit Vice President/General Manager of
Corporate Accounts and Vice President of Commercial and Government
Affairs.
-- In August 2009, Sucampo Pharma Asia completed enrollment into its
open-label phase 3 safety trial and, in October 2009, Sucampo Pharma
Asia completed enrollment into the pivotal phase 3 efficacy trial of
lubiprostone for chronic idiopathic constipation (CIC) in Japan.
-- In September 2009, Sucampo Pharma Europe announced the withdrawal of its
European marketing authorization application (MAA) for lubiprostone, 24
mcg, for the treatment of CIC. The decision to withdraw the MAA was
strategic, based on lubiprostone's projected commercial position in the
global market.
-- In July 2009, Sucampo Pharma Americas reported top-line results from two
identically-designed phase 3 placebo-controlled pivotal clinical trials
of lubiprostone (24 mcg, twice daily) for the management of
opioid-induced bowel dysfunction (OBD) in subjects with chronic,
non-cancer pain. In one trial, the primary endpoint of a statistically
significant change from baseline in the frequency of spontaneous bowel
movements (SBMs) was met when lubiprostone was compared to placebo. The
other trial did not achieve statistical significance for the same
primary endpoint. In both trials, a post-hoc sub-analysis showed that
subjects on methadone treatment regimens who were randomized to receive
lubiprostone showed a lower SBM response when compared to lubiprostone
subjects treated with other opioid medications. The fully-enrolled,
long-term, follow-on, open-label safety study of lubiprostone in OBD
subjects remains ongoing, and Sucampo continues to expect to report data
from this study in late 2009. Sucampo anticipates submitting data from
these trials to the FDA in 2010.
-- In July 2009, Sucampo Pharma Americas reported top-line results from its
phase 2 clinical trial of orally administered cobiprostone for the
prevention of gastric ulcers and other gastrointestinal injuries in
patients treated with non-steroidal anti-inflammatory drugs (NSAID).
Cobiprostone patients experienced an overall statistically significant
reduction in the number of gastric erosions through the treatment period
of twelve weeks compared to placebo patients. In addition, the high-dose
cobiprostone group experienced a 50.0% reduction in the overall
incidence of gastric ulcers when compared to patients taking placebo.
"We continue our review of Takeda's performance regarding the disappointing sales of Amitiza and possible methods to revitalize growth for the product," said Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder, Chairman and Chief Executive Officer. "In the meantime, we continue to push forward in clinical development of Amitiza in other geographies and for other indications, we are preparing for the re-launch of Rescula for glaucoma as well as pursuing Rescula for additional indications with significant market and value potential, and we are proceeding in the development of our other pipeline product candidates."
Financial Results for the Quarter and Year-to-Date
Total revenues for the third quarter of 2009 were $17.8 million, compared to $14.5 million for the third quarter of 2008. Total revenues for the first nine months of 2009 were $51.1 million compared to $95.7 million for the first nine months of 2008. The key elements of the changes in total revenues are:
-- R&D revenue for the third quarter 2009 was $7.0 million, consisting of
$3.5 million recognized primarily for the phase 3 OBD trials funded by
Takeda, and $3.5 million of revenue recognized from the payments
received under the Abbott agreement. R&D revenue for the third quarter
of 2008 was $5.4 million and included revenue recognized with respect to
the development programs for Amitiza in the U.S. supported by Takeda.
R&D revenue for the first nine months of 2009 was $20.0 million compared
to $67.0 million for the first nine months of 2008, which included a
$50.0 million milestone payment from Takeda received and recognized upon
the April 2008 FDA approval of Amitiza (8 mcg) for the treatment of
IBS-C in adult women.
-- Product royalty revenue for the third quarter of 2009 was $9.4 million
compared to $7.7 million during the third quarter of 2008. This increase
is due to a large extent to the third quarter of 2008 being negatively
impacted by lower shipments of Amitiza (8 mcg) subsequent to its initial
stocking completed in the second quarter of 2008. We recognized
approximately $1.9 million of product royalty revenue in the second
quarter of 2008 relating to the initial stocking that was drawn down
over the following two quarters. We note that this will affect
year-over-year comparisons for the fourth quarter of 2009 as well. The
increase also reflects the slight growth in net sales of Amitiza, which
for the three months ended September 30, 2009 and 2008 were
approximately $52.0 million and $50.8 million, respectively. Product
royalty revenue during the nine months ended September 30, 2009 was
$27.2 million, an increase of $2.5 million, or 10.2%, compared to $24.7
million in the prior year period.
Total operating expenses during the third quarter of 2009 were $16.4 million compared to $19.3 million during the third quarter of 2008. Total operating expenses during the nine months ended September 30, 2009 were $51.1 million compared to $62.4 million during the prior year period. The key components of the changes in operating expenses are:
-- R&D expenses during the third quarter of 2009 were $7.4 million, a
decrease of 35.2%, from $11.4 million during the prior year quarter. The
decrease was primarily due to the completion of U.S. clinical trials of
Amitiza and cobiprostone, partially offset by increased expenses from
ongoing phase 3 clinical trials of lubiprostone and phase 1 trials of
SPI-017 in Japanese patients. R&D expenses during the first nine months
of 2009 were $27.0 million, a decrease of 24.1%, from $35.5 million
during the prior year period, which included approximately $2.5 million
of filing and data purchase costs for the European MAA for Amitiza in
Europe.
-- General and administrative (G&A) expenses during the third quarter of
2009 were $4.3 million, an increase of $0.4 million, or 11.8%, from $3.9
million during the prior year quarter, primarily due to $1.4 million in
expenses incurred in the preparation and the on-going conduct of a
performance audit under Sucampo's contract with Takeda and a one-time
business development effort that we elected not to pursue. The increase
was partially offset by a decrease in salaries, benefits and related
costs resulting from cost reduction initiatives implemented at the
beginning of 2009. G&A expenses during the first nine months of 2009
were $10.7 million, an increase of $0.1 million, or 1.0%, compared to
$10.6 million during the prior year period.
-- Selling and marketing (S&M) expenses during the third quarter of 2009
were $3.0 million, an increase of $0.3 million, or 13.7%, as compared to
$2.7 million during the prior year period, primarily resulting from a
one-time expense of $0.7 million incurred upon the withdrawal of
Sucampo's European MAA. The increase was offset in part by savings from
the cost reduction measures in both sales and marketing. S&M expenses
during the first nine months of 2009 were $7.7 million, a decrease of
$0.7 million, or 7.8%, as compared to $8.4 million during the prior year
period, resulting from the cost reduction measures.
Income tax - Sucampo recorded an income tax provision of $1.5 million for the third quarter of 2009 as compared to an income tax benefit of $1.7 million for the third quarter of 2008. Sucampo recorded an income tax provision of $2.7 million for the first nine months of 2009 as compared to $7.2 million for the first nine months of 2008. The income tax benefit/provision relates mainly to the profitable results of Sucampo's U.S. operations.
The financial results for the third quarter of 2009 of Sucampo's reportable segments (United States, Europe and Japan), continue to reflect their respective varying stages of development:
-- Sucampo Pharma Americas recorded income before taxes of $3.6 million for
the third quarter of 2009 compared to a loss before taxes of $2.8
million in the third quarter of 2008. The increase was mainly due to
higher product royalty revenue and decreased R&D expenses due to the
completion of U.S. clinical trials of Amitiza and cobiprostone and
decreased overall preclinical and basic development costs.
-- Sucampo Pharma Europe reported a loss before taxes of $1.5 million for
the third quarter of 2009 compared to a loss before taxes of $0.5
million in the third quarter of 2008, reflecting the expenses incurred
for the European regulatory approval and pre-commercialization
activities for lubiprostone in Europe.
-- Sucampo Pharma Asia reported a loss before taxes of $0.7 million in the
third quarter of 2009 as compared to a loss before taxes of $0.9 million
during the third quarter of 2008. The results reflect the ongoing
investment in the clinical program for lubiprostone and SPI-017 and the
ongoing preclinical programs for other prostone-based compounds.
Sucampo's consolidated cash, cash equivalents and investments totaled $123.6 million at September 30, 2009 as compared with $121.5 million at December 31, 2008. Sucampo Pharmaceuticals, Inc. had no debt as of September 30, 2009.
Company to Host Conference Call Today
Sucampo management will host a conference call today, November 5, 2009 at 4:30 pm Eastern Time to discuss these results. To participate on the live call, please dial 866-783-2138 (domestic) or +1-857-350-1597 (international), and provide the participant passcode 31403000, five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 1-617-801-6888 (international), with the passcode 52346247.
A live and archived audio webcast of the call will be available via the "For Investors" page of the Sucampo Pharmaceuticals website, www.sucampo.com. Please dial in or log on through Sucampo Pharmaceuticals' website approximately 10 minutes prior to the scheduled start time.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Director and Advisor, International Business Development.
Sucampo is marketing Amitiza(R) (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and Amitiza 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Amitiza is registered trademark of Sucampo Pharmaceuticals, Inc. and Rescula is a registered trademark used under license.
Amitiza is co-marketed in the U.S. by Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals, Inc. and its subsidiaries are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Forward-looking statements include statements about potential trial results, the potential utility of Amitiza and Rescula to treat particular indications and expected data availability, trial commencement and regulatory dates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in Sucampo Pharmaceuticals' filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2008 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
(Financial Schedules Follow)
Sucampo Pharmaceuticals, Inc.
Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
Revenues:
Research and development revenue $ 7,045 $ 5,436 $ 19,966 $ 66,982
Product royalty revenue 9,367 7,718 27,227 24,699
Co-promotion revenue 1,266 1,185 3,406 3,643
Contract and collaboration 153 142 451 425
revenue
Total revenues 17,831 14,481 51,050 95,749
Operating expenses:
Research and development 7,383 11,390 26,969 35,537
General and administrative 4,317 3,863 10,696 10,591
Selling and marketing 3,047 2,680 7,747 8,398
Milestone royalties - related - - 875 3,531
parties
Product royalties - related 1,664 1,359 4,837 4,391
parties
Total operating expenses 16,411 19,292 51,124 62,448
Income (loss) from operations 1,420 (4,811 ) (74 ) 33,301
Non-operating income (expense):
Interest income 211 655 742 1,862
Other expense, net (250 ) (15 ) (36 ) (16 )
Total non-operating income (39 ) 640 706 1,846
(expense), net
Income (loss) before income 1,381 (4,171 ) 632 35,147
taxes
Income tax benefit (provision) (1,469 ) 1,745 (2,733 ) (7,192 )
Net income (loss) $ (88 ) $ (2,426 ) $ (2,101 ) $ 27,955
Net income (loss) per share:
Basic net income (loss) per $ - $ (0.06 ) $ (0.05 ) $ 0.67
share
Diluted net income (loss) per $ - $ (0.06 ) $ (0.05 ) $ 0.67
share
Weighted average common shares 41,844 41,813 41,844 41,768
outstanding - basic
Weighted average common shares 41,844 41,813 41,844 42,022
outstanding - diluted
Sucampo Pharmaceuticals, Inc.
Consolidated Balance Sheets (unaudited)
(in thousands, except share data)
September 30, December 31,
2009 2008
ASSETS:
Current assets:
Cash and cash equivalents $ 31,751 $ 11,536
Investments, current 53,038 93,776
Product royalties receivable 9,368 9,725
Unbilled accounts receivable 828 4,373
Accounts receivable 1,350 878
Prepaid and income taxes receivable - 133
Deferred tax assets, net 190 963
Prepaid expenses and other current assets 3,447 3,641
Total current assets 99,972 125,025
Investments, non-current 38,853 16,222
Property and equipment, net 2,357 2,275
Deferred tax assets, non-current 4,216 4,026
Other assets 4,339 3,246
Total assets $ 149,737 $ 150,794
LIABILITIES AND STOCKHOLDERS' EQUITY:
Current liabilities:
Accounts payable $ 2,122 $ 1,433
Accrued expenses 9,414 9,764
Deferred revenue, current 13,499 15,599
Income taxes payable 313 -
Total current liabilities 25,348 26,796
Deferred revenue, non-current 10,217 8,061
Other liabilities 2,110 2,147
Total liabilities 37,675 37,004
Commitments
Stockholders' equity:
Preferred stock, $0.01 par value; $5,000,000 shares
authorized at September 30, 2009 and December 31, - -
2008; no shares issued and outstanding at September
30, 2009 and December 31, 2008
Class A common stock, $0.01 par value; 270,000,000
shares authorized at September 30, 2009 and
December 31, 2008; 15,654,258 and 15,651,849 shares 156 156
issued and outstanding at September 30, 2009 and
December 31, 2008, respectively
Class B common stock, $0.01 par value; 75,000,000
shares authorized at September 30, 2009 and
December 31, 2008; 26,191,050 shares issued and 262 262
outstanding at September 30, 2009 and December 31,
2008, respectively
Additional paid-in capital 98,516 98,243
Accumulated other comprehensive income 454 354
Retained earnings 12,674 14,775
Total stockholders' equity 112,062 113,790
Total liabilities and stockholders' equity $ 149,737 $ 150,794
Sucampo Pharmaceuticals, Inc.
Key Segment Information (unaudited)
(in thousands)
Intercompany
Americas Europe Asia Eliminations Consolidated
Three Months
Ended September
30, 2009
Research and
development $ 3,562 $ - $ 3,483 $ - $ 7,045
revenue
Product royalty 9,367 - - - 9,367
revenue
Co-promotion 1,266 - - - 1,266
revenue
Contract and
collaboration 141 - 282 (270 ) 153
revenue
Total revenues 14,336 - 3,765 (270 ) 17,831
Research and
development 3,040 459 3,884 - 7,383
expenses
Depreciation and 213 3 7 - 223
amortization
Other operating 7,790 1,029 256 (270 ) 8,805
expenses
Income (loss) 3,293 (1,491 ) (382 ) - 1,420
from operations
Interest income 277 - 2 (68 ) 211
Other
non-operating (17 ) (22 ) (279 ) 68 (250 )
expense, net
Income (loss)
before income $ 3,553 $ (1,513 ) $ (659 ) $ - $ 1,381
taxes
Capital $ 64 $ - $ 87 $ - $ 151
expenditures
Three Months
Ended September
30, 2008
Research and
development $ 5,436 $ - $ - $ - $ 5,436
revenue
Product royalty 7,718 - - - 7,718
revenue
Co-promotion 1,185 - - - 1,185
revenue
Contract and
collaboration 142 - 213 (213 ) 142
revenue
Total revenues 14,481 - 213 (213 ) 14,481
Research and
development 10,217 330 843 - 11,390
expenses
Depreciation and 110 1 3 - 114
amortization
Other operating 7,602 139 257 (210 ) 7,788
expenses
Income (loss) (3,448 ) (470 ) (890 ) (3 ) (4,811 )
from operations
Interest income 678 1 2 (26 ) 655
Other
non-operating (6 ) (17 ) (21 ) 29 (15 )
expense, net
Income (loss)
before income $ (2,776 ) $ (486 ) $ (909 ) $ - $ (4,171 )
taxes
Capital $ 5 $ 35 $ - $ - $ 40
expenditures
Nine Months
Ended September
30, 2009
Research and
development $ 12,539 $ - $ 7,427 $ - $ 19,966
revenue
Product royalty 27,227 - - - 27,227
revenue
Co-promotion 3,406 - - - 3,406
revenue
Contract and
collaboration 424 - 717 (690 ) 451
revenue
Total revenues 43,596 - 8,144 (690 ) 51,050
Research and
development 16,398 788 9,783 - 26,969
expenses
Depreciation and 512 9 11 - 532
amortization
Other operating 20,851 1,659 1,803 (690 ) 23,623
expenses
Income (loss) 5,835 (2,456 ) (3,453 ) - (74 )
from operations
Interest income 928 - 4 (190 ) 742
Other
non-operating 191 (392 ) (25 ) 190 (36 )
expense, net
Income (loss)
before income $ 6,954 $ (2,848 ) $ (3,474 ) $ - $ 632
taxes
Capital $ 3,259 $ 3 $ 116 $ - $ 3,378
expenditures
Nine Months
Ended September
30, 2008
Research and
development $ 66,982 $ - $ - $ - $ 66,982
revenue
Product royalty 24,699 - - - 24,699
revenue
Co-promotion 3,643 - - - 3,643
revenue
Contract and
collaboration 425 - 630 (630 ) 425
revenue
Total revenues 95,749 - 630 (630 ) 95,749
Research and
development 29,976 1,703 3,858 - 35,537
expenses
Depreciation and 318 1 7 - 326
amortization
Other operating 25,348 1,188 679 (630 ) 26,585
expenses
Income (loss) 40,107 (2,892 ) (3,914 ) - 33,301
from operations
Interest income 1,924 6 5 (73 ) 1,862
Other
non-operating (39 ) (30 ) (20 ) 73 (16 )
expense, net
Income (loss)
before income $ 41,992 $ (2,916 ) $ (3,929 ) $ - $ 35,147
taxes
Capital $ 304 $ 35 $ 3 $ - $ 342
expenditures
Source: Sucampo Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
